Ibrance® (palbociclib) – Updated label
December 13, 2022 - The FDA approved Pfizer’s Ibrance (palbociclib), for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.
Top